Global Internal Neuromodulation Devices Market Market Growth, Significant Trends Till 2025
Neuromodulation is a technology, which is used to stimulate specific neurological sites or alteration of the nerve activity by using electricity or chemical agents in the body. Most of these devices use electric stimulations. The device is mostly used to treat people suffering from conditions such as tremor, chronic pain, fecal and urinary incontinence, dystonia Parkinson’s disease, epilepsy, and other psychological disorders.
According to Data Bridge Market Research new Market report, “Global Internal Neuromodulation Devices MarketBy Product Type (Spinal Cord Stimulator, Deep Brain Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Gastric Nerve Stimulator), By Indication of Usage (Failed Back Surgery Syndrome, Conditional Regional Pain Syndrome, Eschemia, Parkinson’s Disease, Alzheimers, Urinary Incontinence, Faecal Incontinenece, Epilepsy, Gastroparesis, Others), By Lead Type (Percutaneous, Paddle Lead), By Battery Type (Primary, Rechargeable), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast is projected to reach USD 14.72 billion by 2025, at a CAGR of 15.2% during the forecast period of 2018 to 2025.
Request For sample:- https://databridgemarketresearch.com/request-a-sample/?dbmr=global-internal-neuromodulation-devices-market-4
Global Internal Neuromodulation Devices Market
• In April 2013 boston scientific, launched its Precision Spectra device, pain-relief technology Precision Spectra is used for the treatment of chronic back pain.
• In February 2015, Cyberonics and Sorin group merged and created a new premier global medical technology company. The proposed alliance brought both the global leaders in cardiac surgery and neuromodulation, and the combined company will also be a major player in cardiac rhythm management, especially in Europe and Japan.
• In May 2018, StimGuard LLC, received CE Mark approval for the world’s first wireless programmable neuromodulation device. This device can be introduced through a needle without surgery for treating chronic, intractable symptoms of overactive bladder.
All these technological advancements to treat neurological disorders are showing an optimistic rate of growth in future.
Segmentation: Global Internal Neuromodulation Devices Market
The global market for internal neuromodulation devices by the following sub-categories is presented
By Product Type
1. Spinal Cord Stimulator
2. Deep Brain Stimulator
3. Vagus Nerve Stimulator
4. Sacral Nerve Stimulator
5. Gastric Nerve Stimulator
By Indication of Usage
1. Failed Back Surgery Syndrome
2. Conditional Regional Pain Syndrome
3. Eschemia
4. Parkinson’s Disease
5. Alzheimers
6. Urinary Incontinence
7. Faecal Incontinenece
8. Epilepsy
9. Gastroparesis
10. Others
By Lead Type
1. Percutaneous
2. Paddle Lead
3. By Battery Type
4. Primary
5. Rechargeable
By Geography
1. North America
2. South America
3. Europe
4. Asia-Pacific
5. Middle East and Africa
Request For TOC:- https://databridgemarketresearch.com/toc/?dbmr=global-internal-neuromodulation-devices-market-4
FACTORS DRIVING GROWTH OF THE GLOBAL INTERNAL NEUROMODULATION DEVICES MARKET
Increasing Prevalence of Neurological Diseases:
According to the Alzheimer’s Association in 2017, 5.5 million Americans had Alzheimer and about 5.3 million of this patient population’s age was 65 years or more. According to Alzheimer disease international, in 2015 there were an estimated 46.8 million people living with Alzheimer worldwide this number is expected to be double every 20 years reaching 75 million in 2030 and 131.5 million by 2050.
According to national center for biotechnology information, about 60,000 Americans are diagnosed with Parkinson’s every year. An estimated 7 million to 10 million people worldwide have Parkinson’s disease. The prevalence of this disease is 1,900 per 100,000 in those who are above 80 years of age and 41 per 100,000 in fourth decade of life.
In May 2018, StimGuard LLC, received CE Mark approval for the world’s first wireless programmable neuromodulation device. This device can be introduced through a needle without surgery for treating chronic, intractable symptoms of overactive bladder.
Inquiry Before Buying This:- https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-internal-neuromodulation-devices-market-4
About Us :-Data bridge Market Research is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Contact Us:
Data Bridge Market Research
Toll Free: +1-888-387-2818
Mail: sopan.gedam@databridgemarketresearch.com
According to Data Bridge Market Research new Market report, “Global Internal Neuromodulation Devices MarketBy Product Type (Spinal Cord Stimulator, Deep Brain Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Gastric Nerve Stimulator), By Indication of Usage (Failed Back Surgery Syndrome, Conditional Regional Pain Syndrome, Eschemia, Parkinson’s Disease, Alzheimers, Urinary Incontinence, Faecal Incontinenece, Epilepsy, Gastroparesis, Others), By Lead Type (Percutaneous, Paddle Lead), By Battery Type (Primary, Rechargeable), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast is projected to reach USD 14.72 billion by 2025, at a CAGR of 15.2% during the forecast period of 2018 to 2025.
Request For sample:- https://databridgemarketresearch.com/request-a-sample/?dbmr=global-internal-neuromodulation-devices-market-4
Global Internal Neuromodulation Devices Market
• In April 2013 boston scientific, launched its Precision Spectra device, pain-relief technology Precision Spectra is used for the treatment of chronic back pain.
• In February 2015, Cyberonics and Sorin group merged and created a new premier global medical technology company. The proposed alliance brought both the global leaders in cardiac surgery and neuromodulation, and the combined company will also be a major player in cardiac rhythm management, especially in Europe and Japan.
• In May 2018, StimGuard LLC, received CE Mark approval for the world’s first wireless programmable neuromodulation device. This device can be introduced through a needle without surgery for treating chronic, intractable symptoms of overactive bladder.
All these technological advancements to treat neurological disorders are showing an optimistic rate of growth in future.
Segmentation: Global Internal Neuromodulation Devices Market
The global market for internal neuromodulation devices by the following sub-categories is presented
By Product Type
1. Spinal Cord Stimulator
2. Deep Brain Stimulator
3. Vagus Nerve Stimulator
4. Sacral Nerve Stimulator
5. Gastric Nerve Stimulator
By Indication of Usage
1. Failed Back Surgery Syndrome
2. Conditional Regional Pain Syndrome
3. Eschemia
4. Parkinson’s Disease
5. Alzheimers
6. Urinary Incontinence
7. Faecal Incontinenece
8. Epilepsy
9. Gastroparesis
10. Others
By Lead Type
1. Percutaneous
2. Paddle Lead
3. By Battery Type
4. Primary
5. Rechargeable
By Geography
1. North America
2. South America
3. Europe
4. Asia-Pacific
5. Middle East and Africa
Request For TOC:- https://databridgemarketresearch.com/toc/?dbmr=global-internal-neuromodulation-devices-market-4
FACTORS DRIVING GROWTH OF THE GLOBAL INTERNAL NEUROMODULATION DEVICES MARKET
Increasing Prevalence of Neurological Diseases:
According to the Alzheimer’s Association in 2017, 5.5 million Americans had Alzheimer and about 5.3 million of this patient population’s age was 65 years or more. According to Alzheimer disease international, in 2015 there were an estimated 46.8 million people living with Alzheimer worldwide this number is expected to be double every 20 years reaching 75 million in 2030 and 131.5 million by 2050.
According to national center for biotechnology information, about 60,000 Americans are diagnosed with Parkinson’s every year. An estimated 7 million to 10 million people worldwide have Parkinson’s disease. The prevalence of this disease is 1,900 per 100,000 in those who are above 80 years of age and 41 per 100,000 in fourth decade of life.
In May 2018, StimGuard LLC, received CE Mark approval for the world’s first wireless programmable neuromodulation device. This device can be introduced through a needle without surgery for treating chronic, intractable symptoms of overactive bladder.
Inquiry Before Buying This:- https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-internal-neuromodulation-devices-market-4
About Us :-Data bridge Market Research is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Contact Us:
Data Bridge Market Research
Toll Free: +1-888-387-2818
Mail: sopan.gedam@databridgemarketresearch.com